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Received 22 October 2012Objective: The aim of the present study was to verify the efficacy and the safety of
intratympanic dexamethasone to treat sudden sensorineural hearing loss as salvage
therapy.
Materials and methods: A prospective study was conducted on patients affected by
idiopathic sudden hearing loss who were treated before with some systemic therapy, but
without recovery of the hearing The patients able to undergo the study, but who refused
salvage treatment were considered as control group. A solution of Dexamethasone 4 mg/ml
was then injected through the posterior–inferior quadrant filling completely the middle ear.
The follow-up in the following 6 months included an audiogram every month.
Results: The number of patients treated with salvage therapy was 36. The patients who
refused treatment were further 10. The salvage treatment was done with a mean delay of
24.3 days from the onset of symptoms. Mean hearing threshold after the onset of sudden
hearing loss at PTA was 66.5 dB. After the failed treatment the mean PTA was 59.6 dB. The
mean PTA after the intratympanic steroid administration was 46.8 dB, with a mean
improvement of 12.8 dB. No hearing change was noted in the 10 patients who refused
salvage therapy. The patients that assumed systemic steroid as first therapy showed a
better PTA threshold after the salvage intratympanic treatment (p<0.01). A significant
difference (p<0.05) of hearing recovery was evidenced between non-smoker patients and
those with smoking habit.
Conclusions:Our data showed that a salvage treatment with intratympanic dexamethasone
should be suggested to all patients who failed the first systemic treatment. The systemic
steroid therapy done before the salvage treatment seems to exert a protective role for the
inner ear, as shown by our series. On the contrary the smoke habit is a negative prognostic
factor in the hearing recovery.
© 2013 Elsevier Inc. All rights reserved.mobile).
il.com (F. Dispenza).
er Inc. All rights reserved.
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The loss of hearing of at least 30 dB over at least 3 contiguous
frequencies occurring within 3 days or less is known as
Sudden Sensorineural Hearing Loss (SSHL). In more than
90% of patients, the true cause of the hearing loss is not
discovered, constituting an idiopathic disease. The estimated
incidence of such disease is 5 to 20 cases per 100,000 annually
[1]. However the exact incidence is underestimated, because
many patients who recover early (within first few days) are
unlikely to seek medical care [2]. The rate of spontaneous
recovery is approximately between 32% and 70% which
encourage some otologists not to treat SSHL patients [3].
The lack of consensus in the management of SSHL is due to
difficulty in finding the true etiology of the deafness. Numerous
treatments have been described: steroids, antiviral drugs,
osmotic diuretics, anticoagulants, vasodilators, hyperbaric oxy-
gen, carbogen;most therapies showed somebenefits in restoring
hearing notwithstanding the lack of robustness of the data.
The most widely employed drugs in the management of
SSHL are steroids that are administered as a single agent or
associated with other drugs. Several placebo-controlled trials
reported encouraging results in terms of recovering of hearing
loss [4,5], although other authors discussed such efficacy in
the treatment of SSHL [1,3,6,7].
Although the treatment is started within a reasonable time
after onset of the hearing loss, the result is not always
achieved and about 30%–40% of patients have no benefits after
systemic treatment.
The aim of the present study was to verify the efficacy and
the safety of intratympanic dexamethasone (ITD) to treat
SSHL patients as salvage therapy after other treatments.2. Materials and methods
A prospective study was conducted on patients affected by
idiopathic SSHL who were treated before with some
systemic therapy, but without recovery of the hearing (less
than 10 dB of PTA threshold recovery). The patients includedFig. 1 – Delta PTA (First Therapy PTA − Post Swere referred to our departments from January 2011 to
December 2011. The inclusion criteria were: an SSHL of at
least 30 dB across 3 contiguous frequencies over a period of
3 days and a previous systemic treatment that gave no
recovery of hearing. The patients with the following
characteristic were excluded: history of middle ear pathol-
ogy, previous intratympanic treatments administered else-
where for the same disease. The patient evaluation
included: thorough history, otoscopy, bedside peripheral
vestibular system examination, pure tone audiometry (re-
peated weekly) and MRI of internal auditory canal and
cerebello-pontine angle. History detailed: onset of hearing
loss, otological symptoms related with hearing loss, drugs
consumed in the past days and presence of others systemic
diseases. The bedside examination was done for spontane-
ous and positional nystagmus, Romberg test, Fukuda test,
Halmagyi test and Head Shaking test.
The patients able to undergo the study, but who refused
salvage treatment were considered as control group.
Intratympanic injection was done in supine position with
the head rotated to 45° to the unaffected side. Under
microscope a myringotomy was done in the anterior–inferior
quadrant of the tympanicmembrane in order to allow the exit
of the air in themiddle ear during drug injection. A solution of
Dexamethasone 4 mg/ml was then injected through the
posterior–inferior quadrant filling completely the middle ear.
The patient maintained the position of the head for 20 min
and was instructed to avoid swallowing, speaking and
movements of the head. The intratympanic injection was
repeated five times every two days.
An audiogram was done weekly during the treatment
protocols in both the groups.
The follow-up in the following 6 months included an
audiogram every month.
Patients lost during the follow-up and with evidence of
retrocochlear disease at MRI (i.e.: vestibular schwannoma)
were excluded from the analysis.
A response to the treatment was considered if a change
was recorded in PTA by calculating ΔPTA as the difference
between the PTA before salvage treatment and the last PTA
recorded during follow-up (at least after two months).alvage PTA) in decibel for every patients.
Fig. 2 – Comparison between First Therapy PTA and Post Salvage PTA for each patients.
Table 1 – Sociodemographic characteristics, symptoms,
comorbidities and audiometric outcomes of the patients
with sudden hearing loss (n=46).
Age, mean in years±SD (range) 49.4±14.7 (17–74)
Gender, n (%)
Male 21 (45)
Female 25 (55)
Side, n (%)
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3.5.1 software. All the data were analyzed using the R
statistical software package. Absolute and relative frequencies
were calculated for qualitative variables, while quantitative
variables were summarized as mean (± standard deviation
and range). Categorical variables were analyzed using the chi-
square test (Mantel–Haenszel). Odds ratio (OR) with 95%
confidence intervals (95% CIs) were also calculated. Differ-
ences in means were compared with the Student t-test. All
variables found to have a statistically significant association
(two-tailed p-value <0.05) with improved PTA in the univariate
analysis were included in a multivariate regression model.
The significance level chosen for all analysis was 0.05, two-
tailed. All patients signed an informed consent before the
treatment and our Review Boards approved the present study.Left 23 (50.0)
Right 23 (50.0)
Salvage treatment delay,
mean in days±SD (range)
24.3±23.9 (7–153)
Initial PTA, mean in dB±SD (range) 66.5±17.1 (25–100)
First Therapy PTA,
mean in dB±SD (range)
59.6±16.7 (25–100)
Post Salvage PTA,
mean in dB±SD (range)
46.8±17.9 (10–95)
Delta PTA, mean in dB±SD (range) 12.8±15.2 (49–55)
Vertigo, n (%)
Yes 22 (48)
No 24 (52)
Tinnitus, n (%)
Yes 38 (83)
No 8 (17)
Smokes, n (%)
Yes 14 (30)
No 32 (70)
Diabetes, n (%)
Yes 10 (21)
No 36 (79)
Hypertension, n (%)
Yes 10 (21)
No 36 (79)3. Results
The number of patients treated with salvage therapy was 36,
of which 20 patients were female. The patients who refused
treatment were further 10. The mean age of the whole series
was 49.4 years. The salvage treatment was performed with a
mean delay of 24.3 days from the onset of symptoms and
about 2 days from the end of the first therapy done (Table 1).
Hearing threshold after the onset of sudden hearing loss at
PTA was 66.5 dB (range 25–100 dB; SD ±17.1 dB). After the failed
treatment administered the PTA was 59.6 dB (range 25–100 dB;
SD ±16.7 dB). The PTA after the intratympanic steroid adminis-
tration was 46.8 dB (range 10–95 dB; SD ±17.9 dB), with a mean
improvement of 12.8 dB (SD±15.2 dB) (Figs. 1–2). No hearing
changewasnoted in the10patientswho refusedsalvage therapy.
The otoneurologic symptoms presents in the patients
were: true vertigo in 47.2% and tinnitus in 91.7%. In the
group of salvage treatment 9 patients were smokers of more
than 20 cigarettes per day, 5 patients were diabetics and 5
suffering untreated hypertension.The first treatment administered was a systemic steroid
therapy in 41 patients (89%), of which 22 received also
intravenous osmotic diuretics (i.e. mannitol or glycerol).
Osmotic diuretics alone were administered in 4 patients
unable to take systemic steroids. Hyperbaric oxygen and
Table 2 – FirstApproach treatment of thehearing loss of the
patients treatedwith salvage intratympanic therapy (n=36).
N=36
Steroids therapy, n (%)
Yes 32 (88.9)
No 4 (11.1)
Hyperbaric oxigen, n (%)
Yes 8 (22.2)
No 28 (77.8)
Osmotic diuretics, n (%)
Yes 26 (72.2)
No 10 (28.8)
Antiviral drugs, n (%)
Yes 3 (8.3)
No 33 (91.7)
Table 4 – Average PTA at different stages according to
previous steroids therapy (n=36).
Steroids Therapy p-value
Yes (n=32) No (n=4)
Initial PTA,
mean in dB±SD
64.5±16.7 82.5±13.2 < 0.05
First time PTA,
mean in dB±SD
57.6±15.6 75.0±18.7 < 0.05
Post Salvage PTA,
mean in dB±SD
44.1±15.3 68.7±24.9 < 0.01
Delta PTA,
mean in dB±SD
13.6±15.6 6.3±9.4 0.36
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to 8 and 3 patients (Table 2).
A salvage treatment delay categorization was made in
accordance with median value (20 days). According to salvage
treatment delay categorization there were no statistically
significant differences between a delay less than or equal to
20 days and more than 21 days (Table 3).
The patients that assumed systemic steroid as first therapy
showed a better PTA threshold after the salvage intratympa-
nic treatment (p<0.01) as displayed in Table 4.
A statistically significant difference (p<0.05) of hearing
recovery was evidenced between non-smoker patients and
those with smoking habit, which recovered respectively
(mean) 15.9 dB versus 3.3 dB (Table 5).4. Discussion
The use of intratympanic steroid is a known procedure. Itoh
and Sakata first reported its use in 1991 in treatment of
patients with Meniere's disease [8]. The first use of intratym-
panic therapy in SSHL was described by Silverstein in 1996 [9].
The rationale supporting the ITD administration is the round
windowmembrane permeability to the drugs. Elevated perilym-
phatic concentration of steroids can be achieved after transtym-
panic administration, higher than after systemic administration
[10,11]. The distribution of drugs shows a decreasing concentra-Table 3 – Average PTA at different stages according to
categorization of salvage treatment delay (n=36).
Salvage treatment delay p-value
≤ 20 days
(n=19)
> 21 days
(n=17)
Initial PTA,
mean in dB±SD
62.6±20.8 70.9±10.8 0.33
First time PTA,
mean in dB±SD
56.3±19.5 63.2±12.4 0.18
Post Salvage PTA,
mean in dB±SD
46.8±20.0 46.8±15.9 0.95
Delta PTA,
mean in dB±SD
9.5±11.2 16.5±18.3 0.28tion from basal turn of the cochlea to the apical portion, with
maximum level near the inner aspect of the round window
membrane [12]. The diffusion of molecules into inner ear fluids
and compartments follows different pathways: with perilym-
phatic flow through the helicotrema (longitudinal) and across
the spiral ligament (interscalar communication). Salt et al. found
that whatever protocol adopted, did not influence the relative
distribution of drugs into inner ear fluids, believing that this fact
is secondary to the drug clearance from the perilymph [13].
However the cochlear pharmacokinetics are not clearly under-
stood and the distribution of drugs along the human cochlea is
different than that of rodents used for the study, and in the
opinion of Mikulec et al. it is not a good model [14].
Systemic steroid treatment is widely accepted and recom-
mended as first line therapy in most countries [15] and in our
region correspond to the most adopted protocol of treatment
even when the patients refer to private ENT practitioners or
public ENT ambulatory.
The definition of the true therapeutic intervention on
hearing improvement is difficult to determine because of the
natural history of SSHL includes a high rate of spontaneous
recovery ranging from 31% to 89% [4]. However, the results
presented in the present study confirm the efficacy of ITS as
salvage therapy, although the number of patients was
relatively low, but in line with similar report published.
A hearing improvement in patients with SSHL who failed
to recover with primary systemic therapy was reported by
several authors [16–20]. Also in our study the rate of recovery
after salvage therapy was good and similar to already
mentioned reports. The unchanged hearing recorded in
those patients who refused the salvage treatment was
indicative of the role of the intratympanic treatment in
restoring some hearing function, even if minimal.Table 5 – Average PTA at different stages according to
smoking habit (n=36).
Smoking habit p-value
Yes
(n=9)
No
(n=27)
Initial PTA, mean in dB±SD 62.2±15.1 67.9±17.8 0.39
First time PTA,mean in dB±SD 54.4±15.5 61.3±16.9 0.29
Post Salvage PTA,
mean in dB±SD
51.1±17.8 45.4±18.1 0.41
Delta PTA, mean in dB±SD 3.3±6.6 15.9±16.0 < 0.05
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study was the relationship between smoking habit and
refractoriness to treatment. Several studies have shown
primary tobacco smoke to be associated with a significant
hearing loss risk [21,22]. Smoke consumption has been
reported to be a direct ototoxic agent (nicotine effect) and an
indirect cause of ischemia in the cochlea through production
of carboxyhemoglobin, vasospasm, increased blood viscosity,
and its action in relation to blood vessel atherosclerosis [23].
This study linked the failure of intratympanic salvage therapy
to tobacco smoking, and these data should be kept in mind
when planning some salvage therapy in patients who smoke
cigarettes during treatment.
Furthermore, the data analysis showed that the patients
treated before with systemic steroids had some benefit in the
inner ear homeostasis, although the hearing threshold was
unmodified. All patients treated with steroids as first therapy
had a better response to salvage therapy with some recovery
of the hearing, respect those that had only diuretics or
antiviral drugs.
The steroid action and the sensitivity of the inner ear to
smoke could indicate that the effect of intratympanic steroid
is linked to vascular supply, and to the oxygenation of the
inner ear as consequence.
As shown in our previous report [2], the outcome is not
strictly related to the time of treatment start after the hearing
loss. This was also noted by Parnes et al. who treated 37
patients affected by several inner ear disorders [10] and by Ho
et al. in 39 cases [24]. The absence of relationship between
start of treatment and outcome is very important allowing to
perform an ITS as salvage therapy also after several days of
delay and further diagnostic exams as imaging.5. Conclusions
Our data showed that a salvage treatment with intratympa-
nic dexamethasone should be suggested to all patients who
failed the first systemic treatment. The unchanged hearing
of the group of patients who refused salvage therapy is
indicative of some important action of the steroids into the
cochlear recovery process. The systemic steroid therapy
done before the salvage treatment seems to exert a
protective role for the inner ear, as shown by our series. On
the contrary the smoking habit is a negative prognostic
factor in the hearing recovery. We agree with the last
recommendation of the American Academy in the field of
SSHL [25] that considers the salvage intratympanic steroids
as a recommended therapy.R E F E R E N C E S
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